British Journal of Cancer - Table of Contents alert Volume 107 Issue 6

TABLE OF CONTENTS Volume 107, Issue 6 (901-1008) Published online 4 September 2012 In this issue Editorial Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Occupational Cancer in Britain Lesley Rushton and Gareth Evans with the British Occupational Cancer Burden Study Group Foreword by Kurt Straif This study aims to provide an objective estimate of the burden of cancer in Britain due to occupation. It presents extensive analyses for all carcinogens and occupational circumstances defined as relevant by IARC. The results should help the development of an evidence-based approach for occupational cancer control. Read the articles for FREE   Editorial Top Why are patients with chronic myeloid leukaemia (non-)adherent? I Abraham and K MacDonald Br J Cancer 2012 107: 901-903; 10.1038/bjc.2012.349 Full Text Clinical Studies Top Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study F Efficace, M Baccarani, G Rosti, F Cottone, F Castagnetti, M Breccia, G Alimena, A Iurlo, A R Rossi, S Pardini, F Gherlinzoni, M Salvucci, M Tiribelli, M Vignetti and F Mandelli Br J Cancer 2012 107: 904-909; advance online publication, August 7, 2012; 10.1038/bjc.2012.348 Abstract | Full Text Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies M Jitlal, I Khan, S M Lee and A Hackshaw Br J Cancer 2012 107: 910-917; advance online publication, August 9, 2012; 10.1038/bjc.2012.344 Abstract | Full Text Nomogram prediction for overall survival of patients diagnosed with cervical cancer S Polterauer, C Grimm, G Hofstetter, N Concin, C Natter, A Sturdza, R Pötter, C Marth, A Reinthaller and G Heinze Br J Cancer 2012 107: 918-924; advance online publication, August 7, 2012; 10.1038/bjc.2012.340 Abstract | Full Text Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer V Harding, E Fenu, H Medani, R Shaboodien, S Ngan, H K Li, R Burt, N Diamantis, M Tuthill, S Blagden, H Gabra, C E Urch, S Moser and R Agarwal Br J Cancer 2012 107: 925-930; advance online publication, August 9, 2012; 10.1038/bjc.2012.343 Abstract | Full Text Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery J R Lieffers, O F Bathe, K Fassbender, M Winget and V E Baracos Br J Cancer 2012 107: 931-936; advance online publication, August 7, 2012; 10.1038/bjc.2012.350 Abstract | Full Text Chronic preoperative pain and psychological robustness predict acute postoperative pain outcomes after surgery for breast cancer J Bruce, A J Thornton, N W Scott, S Marfizo, R Powell, M Johnston, M Wells, S D Heys and A M Thompson on behalf of the Recovery Study Group Br J Cancer 2012 107: 937-946; advance online publication, July 31, 2012; 10.1038/bjc.2012.341 Abstract | Full Text BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib M F E Godinho, J D Wulfkuhle, M P Look, A M Sieuwerts, S Sleijfer, J A Foekens, E F Petricoin, III, L C J Dorssers and T van Agthoven Br J Cancer 2012 107: 947-955; advance online publication, August 14, 2012; 10.1038/bjc.2012.351 Abstract | Full Text Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial I Witzel, S Loibl, G von Minckwitz, H Eidtmann, T Fehm, F Khandan, S Schmatloch, M Hauschild, J Bischoff, P A Fasching, C Mau, C Schem, B Rack, I Meinhold-Heerlein, C Liedtke, T Karn, J Huober, C zu Eulenburg, Y Issa-Nummer, M Untch and V Müller Br J Cancer 2012 107: 956-960; advance online publication, August 14, 2012; 10.1038/bjc.2012.353 Abstract | Full Text Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation P Starlinger, L Alidzanovic, D Schauer, T Maier, C Nemeth, B Perisanidis, D Tamandl, B Gruenberger, T Gruenberger and C Brostjan Br J Cancer 2012 107: 961-966; advance online publication, July 31, 2012; 10.1038/bjc.2012.342 Abstract | Full Text Translational Therapeutics Top MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome J Ryan, A Tivnan, J Fay, K Bryan, M Meehan, L Creevey, J Lynch, I M Bray, A O'Meara, A M Davidoff and R L Stallings Br J Cancer 2012 107: 967-976; advance online publication, August 14, 2012; 10.1038/bjc.2012.356 Abstract | Full Text The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas F Seguin, M A Carvalho, D C Bastos, M Agostini, K G Zecchin, M P Alvarez-Flores, A M Chudzinski-Tavassi, R D Coletta and E Graner Br J Cancer 2012 107: 977-987; advance online publication, August 14, 2012; 10.1038/bjc.2012.355 Abstract | Full Text Molecular Diagnostics Top Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma A Kinoshita, H Onoda, N Imai, A Iwaku, M Oishi, N Fushiya, K Koike, H Nishino and H Tajiri Br J Cancer 2012 107: 988-993; advance online publication, August 9, 2012; 10.1038/bjc.2012.354 Abstract | Full Text Genetics and Genomics Top A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas G Dom, M Tarabichi, K Unger, G Thomas, M Oczko-Wojciechowska, T Bogdanova, B Jarzab, J E Dumont, V Detours and C Maenhaut Br J Cancer 2012 107: 994-1000; advance online publication, July 24, 2012; 10.1038/bjc.2012.302 Abstract | Full Text The TERT variant rs2736100 is associated with colorectal cancer risk B Kinnersley, G Migliorini, P Broderick, N Whiffin, S E Dobbins, G Casey, J Hopper, The Colon Cancer Family Registry2, O Sieber, L Lipton, D J Kerr, M G Dunlop, I PM Tomlinson and R S Houlston The CORGI Consortium Br J Cancer 2012 107: 1001-1008; advance online publication, August 9, 2012; 10.1038/bjc.2012.329 Abstract | Full Text Advertisement BJC's new impact factor is 5.042! Thank you to all our authors, readers, editors, and reviewers Check out some top cited BJC papers: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Guidelines for the welfare and use of animals in cancer research The role of microRNAs in liver cancer progression Fruit and vegetables and cancer risk Hypoxia inducible factors in cancer stem cells   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.